



AQUA BIO TECHNOLOGY ASA

Second Quarter 2015 Results Presentation

19 August 2015



Q2 2015 Highlights


- Revenue stream as agreed in exclusivity contracts
- Best first half year in Company history
- EBITDA margin well above 50 per cent both in quarter and first half year 2015
- Financial position remains strong
 - *NOK 32 million cash reserve*

Income Statement


<i>NOK million</i>	<i>Q2 2015</i>	<i>Q2 2014</i>	<i>YTD 2015</i>	<i>YTD 2014</i>
Income	9.0	5.2	18.1	10.6
Operating costs	-4.3	-5.4	-8.1	-9.6
EBITDA	4.7	-0.2	10.0	1.0
EBIT	3.1	-1.8	6.7	-2.2
EBT	3.2	-1.7	7.3	-2.1
Net result	3.2	-1.7	7.3	-2.1
EBITDA margin	52.2%	-3.3%	55.2%	9.5%

- Royalty and exclusivity payments received according to contracts
- Revenues may fluctuate significantly from quarter to quarter
- 2014 results affected by legal dispute in the United States

Income and results development



Sales



EBITDA

Balance Sheet

<i>NOK million</i>	<i>30 June 2015</i>	<i>31 December 2014</i>	<i>30 June 2014</i>
Fixed assets	10.3	12.4	15.4
Current assets	65.6	63.4	61.1
- <i>of which is cash</i>	31.8	29.2	27.1
Total equity	66.6	66.3	63.9
Long term debt	5.3	5.6	7.6
Short term debt	4.0	3.9	4.9
Total balance	75.9	75.8	76.5
Equity ratio	87.8%	73.8%	83.6%

- ABT paid its shareholders a total of NOK 6.4 million in ordinary and extraordinary dividend in June 2015.

Cash flow

<i>NOK million (Year to date)</i>	<i>2015</i>	<i>2014</i>
Cash at beginning of period	29.2	27.0
From operations	10.0	3.5
From investments	-1.1	-2.0
From financing	-7.0	-1.4
Currency effects	0.7	0.0
Cash at end of period	31.8	27.1
Cash change in period	2.6	0.1

- ABT paid its shareholders a total of NOK 6.4 million in ordinary and extraordinary dividend in June 2015.

A strategy for expansion

1.	Support exclusivity partners Restorsea and Amway in their efforts to reach commercial success in the cosmetics market with skin care products based on ABT technology.	<i>Ongoing</i>
2.	<i>Active in-licensing of relevant technologies from partners; develop ABT as a powerhouse in commercializing third party technologies for skin care and other applications.</i>	<i>Ongoing</i>
3.	<i>Explore possible applications for medical use.</i>	<i>Initiated</i>

Outlook

- Continued strong revenue stream
 - *Contracted revenue and exclusivity and royalty payments until 2017*
 - *Commercial success of exclusivity partners represent upside potential*
- Strategy of broadened market approach holds potential
 - *Search, and evaluation of in-licensing candidates continues*
 - *Medical market may represent significant long term potential*
 - *Other market segments under review*
- Robust financial position
 - *Equity ratio 87 per cent; strong cash position*

3rd Quarter 2015 Results
18 November 2015



abt

AQUA BIO TECHNOLOGY ASA

Investor contact

Arvid Lindberg, CEO

+47 9824 5410

arvid@aquabiotech.no

www.aquabiotechnology.com